Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

abiraterone acetate

- PMLiVE

Sales rise but profits fall at J&J in Q3

Failed clinical programmes and Synthes acquisition hit net results

- PMLiVE

Lilly’s gastric cancer prospect clears phase III trial

Ramucirumab improved both overall and progress-free survival

Roche - Basel

Roche Q3 sales up on cancer drugs

And CEO Schwan commits to gene sequencing despite failed Illumina bid

Celgene’s Abraxane receives FDA approval in lung cancer

Adds to current breast cancer indication

AZ’s MedImmune partners with global cancer institutes

Will research combinations of immunotherapies

- PMLiVE

Janssen unveils €30,000 prize fund for health tech innovation

Will look for 'transformational ideas' in homecare, adherence and personal health management

Roche: Scotland must improve cancer drug access

Pharma company's call comes as SMC decides not to recommend Avastin in ovarian cancer

Study shows Sanofi’s Zaltrap effective in colorectal cancer

Reinforces prospects following US approval

- PMLiVE

AZ pays $273m for Ardelyx renal disease drug

Phase II candidate could tackle fluid overload in kidney and heart disorders

Janssen adds Astellas JAK inhibitor to its immunology portfolio

Licenses oral rheumatoid arthritis and psoriasis candidate ASP015K

Daiichi and ArQule pull late-stage study of lung cancer drug

Fails to reach primary endpoint of overall survival

Roche - Basel

Roche’s T-DM1 activity in breast cancer “outstanding”

Improves survival by six months compared to GSK’s Tykerb/Tyverb

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links